Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenprobamate is a centrally acting skeletal muscle relaxant with additional sedative and anticonvulsant effects. It is used primarily for the treatment of pain caused by muscle spasms, as well as for muscle cramps, spasticity, and occasionally as an anxiolytic or adjunct in general anesthesia. Its mechanism of action is believed to be similar to that of meprobamate—likely involving positive modulation of the GABA A receptor—though the precise molecular target has not been definitively established. Phenprobamate has been largely replaced by newer agents but remains available over-the-counter in some European countries and has also been marketed as a nootropic. The drug is metabolized via oxidative degradation of its carbamate group and ortho-hydroxylation of its benzene ring; it is eliminated renally with an elimination half-life of 5–8 hours[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenprobamate.